Harold Keer
Chief Medical Officer Taiho Oncology
Currently CMO at Taiho Oncology, Inc, overseeing R&D. Recent approvals and filings for small molecules. Previously CMA at Astex Pharmaceuticals. MD,PhD from Northwestern and trained in Internal Medicine at Beth Israel followed by Oncology at Stanford. Please check TOI website for further details.
Seminars
Monday 8th March 2027
Use of Unique Linkers to Control DAR & Mitigate Associated ADC Toxicity for Potential Use in Combination with Existing Anticancer Treatments
1:30 pm
- Sharing a general ADC concept and linker technology approach
- Presenting the Taiho & Araris-based programs with our approach and strategy
- Determining potential usability of combinations with existing anticancer treatments
